11 min read
Monthly FDA Guidance and Regulatory News Review - June 2026
This June 2026 regulatory update focuses on advancing innovative drug development through updated guidance on...
Meet Veristat at the Advanced Therapies Congress 2025
Veristat is excited to participate in the Advanced Therapies Congress, Europe’s largest commercial cell and gene therapy conference and exhibition. Join us at the ExCeL in London, March 18-19, to explore the latest advancements in cell and gene therapy.
Powering Data Insights, Trial Optimization, and Results
At Veristat, we are committed to helping sponsors accelerate the development and approval of transformative therapies. Our teams specialize in clinical trial execution, regulatory consulting, and strategic planning, with extensive experience in cell and gene therapy programs. From preclinical studies to global regulatory approval, we provide customized solutions to meet the unique challenges of these therapies.
Accelerating Advanced Therapy Development
Highlights of our expertise include:
Supporting 350+ rare and ultra-rare disease programs in the past five years
Guiding sponsors through accelerated regulatory pathways such as Orphan Drug Designation and Priority Review
Collaborating with global health authorities, including the FDA, EMA, and MHRA, to secure approvals for advanced therapies
Whether it’s solving patient recruitment challenges, optimizing trial designs, or ensuring regulatory compliance, Veristat’s scientific-minded teams are here to help remove barriers to expand treatment access for patients.
Connect with Veristat:
David Chia- Senior Business Development Director
Schedule a meeting with David to discuss how Veristat can help accelerate your cell and gene therapy programs to bring them to patients sooner. Learn more about the conference
Learn more about the conference
2 min read
FDA Prior Knowledge Guidance: A New Framework for Natural History Evidence
Jul 2, 2026 Veristat Blog
June 22, 2026
What the FDA's prior knowledge guidance means for natural history evidence and shared datasets
On June 2,...